



NCCN Trends™ is an analytics tool from the National Comprehensive Cancer Network® (NCCN®) that surveys how clinicians across the U.S. and around the globe are delivering cancer care. This summary includes the results of the March 2013 NCCN Trends™ Survey, which focused on Chronic Myelogenous Leukemia. This survey was sent to U.S. and International users of NCCN.org.

DEMOGRAPHICS

Distribution of Respondent Types (n = 889)




Q1. Do you treat patients with chronic myelogenous leukemia (CML)? (n = 889)



Results: March 2013
CHRONIC MYELOGENOUS LEUKEMIA


Q2. How often do you monitor your patients with CML with quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) for a treatment response? (n = 508)



Q2. How often do you monitor your patients with CML with quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) for a treatment response?

By Geography †

- Patients are monitored every *3 months* in a lab *standardized* to the International Scale (IS) as recommended by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®])
- Patients are monitored every *3 months* in a lab *not standardized* to the International Scale (IS)
- Patients are monitored every *6 months* in a lab *standardized* to the International Scale (IS)
- Patients are monitored every *6 months* in a lab *not standardized* to the International Scale (IS)
- Patients are monitored *once a year* in a lab *standardized* to the International Scale (IS)
- Patients are monitored *once a year* in a lab *not standardized* to the International Scale (IS)
- Patients are not monitored for response using qRT-PCR
- Not sure




†Note: Percentages may not total 100 because of rounding.

Q2. How often do you monitor your patients with CML with quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) for a treatment response?

By Practice Size †

- Patients are monitored every *3 months* in a lab *standardized* to the International Scale (IS) as recommended by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®])
- Patients are monitored every *3 months* in a lab *not standardized* to the International Scale (IS)
- Patients are monitored every *6 months* in a lab *standardized* to the International Scale (IS)
- Patients are monitored every *6 months* in a lab *not standardized* to the International Scale (IS)
- Patients are monitored *once a year* in a lab *standardized* to the International Scale (IS)
- Patients are monitored *once a year* in a lab *not standardized* to the International Scale (IS)
- Patients are not monitored for response using qRT-PCR
- Not sure




†Note: Percentages may not total 100 because of rounding.

Q2. How often do you monitor your patients with CML with quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) for a treatment response?

By Practice Setting †

- Patients are monitored every 3 months in a lab standardized to the International Scale (IS) as recommended by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®])
- Patients are monitored every 3 months in a lab not standardized to the International Scale (IS)
- Patients are monitored every 6 months in a lab standardized to the International Scale (IS)
- Patients are monitored every 6 months in a lab not standardized to the International Scale (IS)
- Patients are monitored once a year in a lab standardized to the International Scale (IS)
- Patients are monitored once a year in a lab not standardized to the International Scale (IS)
- Patients are not monitored for response using qRT-PCR
- Not sure




†Note: Percentages may not total 100 because of rounding.

Q2. How often do you monitor your patients with CML with quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) for a treatment response?


By Specialty †

- Patients are monitored every *3 months* in a lab *standardized* to the International Scale (IS) as recommended by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®])
- Patients are monitored every *3 months* in a lab *not standardized* to the International Scale (IS)
- Patients are monitored every *6 months* in a lab *standardized* to the International Scale (IS)
- Patients are monitored every *6 months* in a lab *not standardized* to the International Scale (IS)
- Patients are monitored *once a year* in a lab *standardized* to the International Scale (IS)
- Patients are monitored *once a year* in a lab *not standardized* to the International Scale (IS)
- Patients are not monitored for response using qRT-PCR
- Not sure



†Note: Percentages may not total 100 because of rounding.


Q3. Mutational analysis is performed on your patients with CML... (please complete the statement, select all that apply)



Q3. Mutational analysis is performed on your patients with CML... (please complete the statement, select all that apply)

By Geography †



- US Midwest
- US Northeast
- US South
- US West
- Europe
- Latin America
- Asia
- Other Non-US



†Note: Percentages may not total 100 because of rounding.

Q3. Mutational analysis is performed on your patients with CML... (please complete the statement, select all that apply)


By Practice Size



Q3. Mutational analysis is performed on your patients with CML... (please complete the statement, select all that apply)

By Practice Setting †



■ Academic Setting
 ■ Community Setting



†Note: Percentages may not total 100 because of rounding.


Q3. Mutational analysis is performed on your patients with CML... (please complete the statement, select all that apply)

By Specialty †



†Note: Percentages may not total 100 because of rounding.


Q4. Following a mutational analysis test on your patients with CML, when do you decide to switch or modify therapy? (select all that apply) (n = 382)



Q4. Following a mutational analysis test on your patients with CML, when do you decide to switch or modify therapy? (select all that apply)

By Geography †

- US Midwest
- US Northeast
- US South
- US West
- Europe
- Latin America
- Asia
- Other Non-US




†Note: Percentages may not total 100 because of rounding.

Q4. Following a mutational analysis test on your patients with CML, when do you decide to switch or modify therapy? (select all that apply)

By Practice Size †

- 1 to 3
- 4 to 9
- 10 or more




†Note: Percentages may not total 100 because of rounding.

Q4. Following a mutational analysis test on your patients with CML, when do you decide to switch or modify therapy? (select all that apply)

By Practice Setting


■ Academic Setting
■ Community Setting



Q4. Following a mutational analysis test on your patients with CML, when do you decide to switch or modify therapy? (select all that apply)


By Specialty †

- Medical Oncology
- Radiation Oncology
- Surgical Oncology
- Hematology or Bone Marrow Transplant
- Internal Medicine
- General Surgery
- Other



†Note: Percentages may not total 100 because of rounding.


Q5. Assuming compliance or drug-drug interactions are not factors, what would be your next step if your patients did not achieve a $\leq 10\%$ BCR-ABL response by qRT-PCR at 3 months? (select all that apply) (n = 464)



Q5. Assuming compliance or drug-drug interactions are not factors, what would be your next step if your patients did not achieve a $\leq 10\%$ BCR-ABL response by qRT-PCR at 3 months? (select all that apply)

By Geography †



- US Midwest
- US Northeast
- US South
- US West
- Europe
- Latin America
- Asia
- Other Non-US



†Note: Percentages may not total 100 because of rounding.

Q5. Assuming compliance or drug-drug interactions are not factors, what would be your next step if your patients did not achieve a $\leq 10\%$ BCR-ABL response by qRT-PCR at 3 months? (select all that apply)

By Practice Size †




†Note: Percentages may not total 100 because of rounding.

Q5. Assuming compliance or drug-drug interactions are not factors, what would be your next step if your patients did not achieve a $\leq 10\%$ BCR-ABL response by qRT-PCR at 3 months? (select all that apply)



By Practice Setting

■ Academic Setting
 ■ Community Setting



Q5. Assuming compliance or drug-drug interactions are not factors, what would be your next step if your patients did not achieve a $\leq 10\%$ BCR-ABL response by qRT-PCR at 3 months? (select all that apply)

By Specialty †



†Note: Percentages may not total 100 because of rounding.
 © National Comprehensive Cancer Network, Inc. 2013, All Rights Reserved. For Personal Use Only.
 This report may not be reproduced or distributed beyond personal use in any form without the express written permission of NCCN.

NCCN Trends™ is an analytics tool from the National Comprehensive Cancer Network® (NCCN®) that surveys how clinicians across the U.S. and around the globe are delivering cancer care. NCCN Trends™ surveys are designed to reach targeted populations that can include several thousand clinicians as a potential sample size. NCCN can also provide analytics on existing NCCN Trends™ and clinician demographic data sets, allowing for greater insight into oncology practice patterns.

To commission an **NCCN Trends™** survey, to discuss analytic and data services, or to request information on other NCCN programs and resources, please contact:

Christine MacCracken, MSHEd, BSN
Senior Director, Business Insights
215.690.0557
maccracken@nccn.org

National Comprehensive Cancer Network® (NCCN®)

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 21 of the world's leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.



National
Comprehensive
Cancer
Network®

275 Commerce Drive • Suite 300
Fort Washington, PA, 19034
Telephone: 215.690.0300
Fax: 215.690.0280

NCCN.org - For Clinicians • NCCN.com - For Patients

*All NCCN Trends™ survey content and resulting data are owned by NCCN. Survey responses are made anonymous to protect the privacy of survey respondents. NCCN may license survey content, data, and analytic results to third parties, but retains the rights to use this data for other purposes, including the support of educational and research efforts or for other strategic or business purposes.